Mylan Laboratories, Inc. has signed a definitive agreement to acquire Merck KGaA’s generics business (Merck Generics) for $6.7 billion in cash. The combination of the two companies will create an integrated global generics and specialty pharmaceuticals company with differentiated dosage form expertise and increased API capacity. On a pro forma basis, combined 2006 revenues were $4.2 billion, EBITDA was approximately $1 billion, and the integrated company will have approximately 10,000 empl...